Across TCGA pan-cancer cohorts, ZNF830 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF830 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNF830 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF830 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and GBM are the cancer types where ZNF830 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.617	0.279	<.001	49	view →
LUAD	DFS	Median	All	0.961	0.644	.004	22	view →
GBM	OS	Quartile	All	0.562	0.281	.007	9	view →
CCRCC	OS	Median	III,IV	1.000	0.353	.022	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZNF830 tumor-vs-normal RNA expression · all ZNF830 data types